ERBB2 and breast carcinoma: In the intratibial BT-474 model mimicking bone-metastasized breast cancer, HER2-TTC at both 250 and 500 kBq/kg effectively prevented both tumor growth and tumor-induced abnormal bone growth as analyzed via histology and micro-CT or X-ray imaging, respectively.